Generative AI's Role in Healthcare Innovation With: Tom Neyarapally
In this full interview, Tom Neyarapally, CEO and Co-Founder of Archetype Therapeutics, discusses the transformative role of AI in drug development. He explores how generative AI is accelerating drug discovery, enabling drug repurposing, and reshaping therapeutic innovation. Neyarapally provides a forward-looking perspective on the future of AI in healthcare, drawing from his deep expertise and hands-on leadership in the biotech industry.
Episode Contents:
Key Takeaways
- Generative AI accelerates drug discovery
- AI enables efficient drug repurposing
- Future of healthcare innovation is AI-driven
Transcript Summary
Q: How is AI impacting drug development?
A: AI is transforming early-stage research, enabling faster and more accurate target identification.
Q: What role does generative AI play in drug discovery?
A: Generative AI designs new molecules, predicting efficacy and safety with high precision.
Q: How does AI help with drug repurposing?
A: It analyzes existing compounds for new therapeutic uses, shortening timelines and reducing costs.
More Topics
- AI in the Healthcare Industry
- AI and Medical Innovation
- Healthcare Ethics and Policy
- AI in Patient Care
Keep Exploring
About the Series
AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine.
Dr. Sanjay Juneja, a hematologist and medical oncologist widely recognized as “TheOncDoc,” is a trailblazer in healthcare innovation and a rising authority on the transformative role of AI in medicine.
Mika Newton is an expert in healthcare data management, with a focus on data completeness and universality. Mika is on the editorial board of AI in Precision Oncology and is no stranger to bringing transformative technologies to market and fostering innovation.